Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $2.6652W HIGH $6.42
Volume
21.22 K
Value Traded
128.31 K
Short % Float
0.29%
Days to Cover
1.4
-2.45%Week
-10.92%1 Month
+4.66%3 Month
+11.15%6 Month
-57.53%5 Year
-99.68%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
39.02 M
EPS (TTM)
0.16
P/E Ratio
22.45
Ent. Value
34.33 M
Total Shares
10.87 M
Float Shares
8.75 M
Insiders
19.47%
Institutions
17.81%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
NEPH Catalyst Timeline
Dated clinical, regulatory and corporate events for Nephros, Inc.
Past FDA Catalysts and PDUFA Decisions
How NEPH actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
Nephros, Inc. is a medical device company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every NEPH program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| WEXFORD CAPITAL LP10% Owner | Option | 812 56,872 held | $3.60 | 08/18/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in NEPH
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in NEPH for Q2 2026. | ||||
NEPH Institutional Ownership Trends
NEPH Short Interest
Shares sold short, counted twice a month.
0.29%
Short % of Float
of tradable shares sold short
25.3K
Shares Sold Short
-45.5% vs prior count
1.4 Low
Days to Cover
trading days of normal volume to buy every short share back
18.3K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How NEPH ranks across every disease it competes in
Competitive Position is a premium feature
See how NEPH ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialNEPH News
NEPH▲ +17.3%on this news
Nephros Announces Strong Financial Results for Quarter Ended June 30, 2026
Nephros, Inc. reported strong financial results for Q2 2026, achieving a record net revenue of $6 million, a 36% increase from the previous year. The company's core programmatic revenue grew by 27%, reflecting robust demand and successful product launches. Despite challenges such as increased costs and expenses, Nephros remains optimistic about its growth trajectory and market position.
Read more →NEPHNephros Schedules Second Quarter 2026 Financial Results Conference Call
Nephros, Inc. has announced the scheduling of its second quarter 2026 financial results conference call for August 6, 2026, after market close. Participants can join via domestic and international dialing options. An audio archive will be available post-call, and the company emphasizes its commitment to water safety through innovative filtration solutions.
Read more →NEPHNephros to Participate in the “Health, Wellness & Longevity” Virtual Conference Presented by Maxim Group LLC on Wednesday, July 22nd at 10:00 a.m. ET
Nephros, Inc. announced its participation in the upcoming virtual conference titled 'Health, Wellness & Longevity' organized by Maxim Group LLC. CEO Robert Banks will present at the event, which aims to discuss innovations in consumer health and wellness. The conference will take place on July 22, 2026, and is accessible to institutional investors.
Read more →NEPHNephros Announces Inclusion in the Russell Microcap® Index
Nephros, Inc. has announced its inclusion in the Russell Microcap® Index, effective June 26, 2026. This membership is expected to enhance the company's visibility and attract new institutional investors, following a year of significant achievements. CEO Robert Banks expressed optimism regarding the potential long-term value for shareholders.
Read more →NEPHNephros to Host Virtual Investor Event: “Beyond Filtration: The Nephros Model in Action”
Nephros, Inc. will host a virtual investor event titled 'Beyond Filtration: The Nephros Model in Action' on July 16, 2026. The event will highlight the company's approach to redefining water safety and its scalable model beyond filtration. Attendees will gain insights from industry leaders and participate in a Q&A session with Nephros leadership.
Read more →NEPHNephros Positions Ultrafiltration Technology as a Solution to Emerging Microplastic Risk in Water
Nephros, Inc. has emphasized the effectiveness of its ultrafiltration technology in capturing microplastics and nanoplastics, following the U.S. EPA's decision to classify microplastics as a priority contaminant. The company's filters, designed with small pore sizes, are positioned to meet emerging water quality challenges. This advancement aligns with a shift towards proactive water management solutions.
Read more →NEPHNephros Announces Financial Results for Quarter Ended March 31, 2026
Nephros, Inc. reported financial results for the quarter ending March 31, 2026, highlighting a 7% increase in net revenue to $5.2 million. The company achieved a significant milestone by surpassing $5 million in quarterly revenue for the first time. However, net income fell to $140,000 compared to $558,000 in the previous year, attributed to tariff impacts and rising costs. While management remains optimistic about long-term growth prospects, recent shifts in revenue mix could affect margins in the near term.
Read more →NEPH▼ -7.9%on this news· ran to -23% by day 1
Nephros Announces Fourth Quarter and Record Fiscal Year 2025 Financial Results
Nephros, Inc. reported a strong financial performance for Q4 and fiscal year 2025, achieving a 33% increase in net revenue year-over-year. The company also noted positive net income for the second consecutive year, driven by growth in its product and service offerings. However, challenges such as decreased gross margins and the impact of tariffs were highlighted.
Read more →NEPHNephros Schedules Fourth Quarter 2025 Financial Results Conference Call
Nephros, Inc. has announced the scheduling of its fourth-quarter financial results conference call for March 12, 2026. The call will take place at 4:30 PM ET, following the release of the financial results after market close. Participants can join via domestic and international access numbers, and a replay will be available until March 19, 2026.
Read more →NEPH▲ +9%on this news
Nephros Expands into Puerto Rico to Deliver Differentiated Water Filtration Solutions Across Medical and Commercial Sectors
Nephros, Inc. has announced its expansion into the Puerto Rican market, focusing on providing advanced water filtration solutions for various sectors, including healthcare and foodservice. The company aims to address significant unmet needs in waterborne pathogen control, estimating a $10 million market opportunity. Nephros plans to differentiate itself through localized service and language-specific support.
Read more →NEPHNephros Launches the Nephros Water Institute to Lead National Water Safety Education
Nephros, Inc. has launched the Nephros Water Institute to enhance national water safety education. This initiative aims to address critical gaps in understanding water safety risks through structured educational programs. The company has already reached nearly 1,000 professionals and plans to expand its educational efforts with monthly webinars in 2026. Nephros emphasizes the importance of practical information for stakeholders responsible for water safety.
Read more →NEPHNephros Announces Strong Second Quarter Financial Results
Nephros, Inc. announced strong financial results for the second quarter of 2025, highlighting a 36% increase in net revenue to $4.4 million compared to the same period in 2024. The company reported net income of $237,000, marking its third consecutive quarter of profitability. Both adjusted EBITDA and revenue for the first half of 2025 also saw substantial growth. Nephros credits its success to disciplined execution, innovation, and a robust expansion of its customer base, particularly in its dialysis water segment, which recorded significant sales.
Read more →NEPHNephros Announces Financial Results for Quarter Ended March 31, 2025
Nephros, Inc. announced its financial results for Q1 2025, reporting a net revenue of $4.9 million, marking a 38% increase from the same period last year. The company achieved a net income of $558,000, a notable improvement from a net loss of $169,000 in Q1 2024. The CEO highlighted strong performance in both programmatic and emergency response business segments, although he noted potential challenges due to macroeconomic uncertainties and regulatory changes. Overall, the results reflect growing demand and operational success, with optimism for sustained growth.
Read more →NEPHNephros Announces Fourth Quarter and Fiscal Year 2024 Financial Results
Nephros, Inc. released its financial results for Q4 and fiscal year 2024, showing a net revenue of $14.2 million for the year, consistent with the previous year. The fourth quarter saw a 19% increase in net revenue compared to Q4 2023, reaching $3.9 million, and the company achieved its first net income of $349,000 in the quarter. Despite meeting overall revenue expectations, challenges in the emergency response sector were noted, which the company managed to overcome with growth in core programmatic business. The launch of the new HydraGuard Ultrafilter is expected to enhance their market position.
Read more →NEPHNephros, Inc. 380 Lackawanna Place South Orange NJ 07079 Call: 201 343 5202 nephros.com Nephros Announces Financial Results for Quarter Ended
Nephros, Inc. reported its financial results for the third quarter ending September 30, 2024, achieving a net income of $0.2 million, marking the company's first profitable quarter. Despite this positive development, the firm's revenue of $3.5 million reflects a 6% decrease compared to the same period in the previous year. Operational improvements contributed to a significant rise in adjusted EBITDA to $295,000, but challenges persist with underperformance in the South Central sales region and slower ordering patterns from larger accounts. Nephros continues to focus on enhancing operational efficiency and mitigating programmatic reorder reductions.
Read more →NEPHNephros, Inc. 380 Lackawanna Place South Orange NJ 07079 Call:201 343 5202 nephros.com Nephros Announces Fourth Quarter and Fiscal Year 2023 Financial Results Full-Year Net Revenue of $14.2 Million and Fourth-Quarter Net
Nephros, Inc. reported its financial results for the fourth quarter and fiscal year 2023, showcasing a significant net revenue increase of 43% from the previous year, totaling $14.2 million. The adjusted EBITDA loss improved notably, reflecting enhanced operational efficiency. However, the company continued to post net losses, with a net loss of $1.6 million for the year. Nephros' CEO expressed optimism regarding the company's positioning in the market due to new water safety guidelines and operational improvements.
Read more →NEPHNephros, Inc. 380 Lackawanna Place South Orange NJ 07079 Call: 201 343 5202 nephros.com Nephros Hires Judy Krandel as Chief Financial Officer
Nephros, Inc. has appointed Judy Krandel as its new Chief Financial Officer, effective immediately. Krandel has over 20 years of experience in financial leadership, which includes roles in asset management, investment, and financial oversight. She aims to enhance the company's financial operations and contribute to its growth strategy during a time of increasing revenues and cash flow. Her previous experience includes serving as CFO for several public companies where she focused on growth and capital allocation strategies.
Read more →NEPHNephros, Inc. 380 Lackawanna Place South Orange NJ 07079 Call: 201 343 5202 nephros.com Nephros Announces Results for Quarter Ended
Nephros, Inc. reported its financial results for the second quarter ended June 30, 2023, showcasing a net revenue of $3.5 million, reflecting a 24% increase year-over-year. While the company achieved positive cash flow and improved gross margins to 59%, it also recorded a net loss of $0.4 million. The number of Active Customer Sites grew by 6%, indicating growth in customer engagement. Despite these gains, Nephros continues to operate with an Adjusted EBITDA loss, raising concerns about profitability.
Read more →NEPHNephros, Inc. 380 Lackawanna Place South Orange NJ 07079 Call: 201 343 5202 nephros.com Nephros Announces CEO Retirement and Succession Plan Robert Banks to Be Named President and Chief Executive Officer; Andy Astor to R
Nephros, Inc. has announced the retirement of CEO Andy Astor, who will be succeeded by Robert Banks. The transition follows Nephros achieving cash-flow breakeven and strong revenue growth of 40% year-over-year in 2023. Astor will remain with the company as an advisor and interim CFO while a search for a permanent CFO is conducted. The board expresses confidence in Banks' abilities to lead the company forward in a strong market position.
Read more →About Nephros, Inc.
Headquarters380 LACKAWANNA PLACE, SOUTH ORANGE, NJ, 07079
BIOPHARMAWATCH ELITE PLUS
Trade the next NEPH catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime